Galectin updates fatty liver disease trial, reports Q3 results, shares fall

Galectin Therapeutics (GALT -10.7%) drops after reporting Q3 results.

The company says "five of the eight patients have been enrolled and infused" in a Phase 1 study of GR-MD-02 in NASH.

Data from the first cohort of patients is due early next year assuming "all goes as expected."

As of September 30, GALT had $9.7M in cash which the company says should last "into Q3 of 2014." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs